Behc ßet's disease (BD) is a chronic, relapsing, inflammatory multisystem disease of unknown etiology. Oral ulcers, genital ulcers, cutaneous lesions, and ocular and articular involvement are the most frequent features of the disease. Mucocutaneous lesions are considered hallmarks of the disease, and often precede other manifestations.
the US mainland or Hawaii, and Turkish immigrants in Germany. In earlier studies, BD has been reported to be extremely rare among Japanese immigrants in California or Hawaii. 8 In the city of Berlin, risk of developing BD was found to be substantially higher in Turkish immigrants (77.3%/100 000) than Germans (1.47%/100 000) and non-Germans (excluding Turks) (26.6%/100 000), although it was still below the reported risk in Turkey. 9 In contrast to the previous two studies, Mahr et al. 10 suggested that genetic factors may be more effective than environmental factors on the incidence of the disease. In a cross-sectional prevalence study in the suburbs of Paris, Mahr et al. reported the frequency of BD as 7.1/100 000. BD among immigrants of North African (34.6/100 000) or Asian ancestry (17.5/100 000) is significantly higher than that in the Europeanorigin population (2.4/100 000), and comparable with rates reported from North Africa and Asia. Within the migrant population of either North African or Asian ancestry, BD prevalences were similar for residents born in France. Therefore, authors concluded that BD risk is not related to age at immigration and the disease has a primarily hereditary basis. 9 Gastrointestinal involvement is more common among the patients from Japan and Korea compared with other countries such as Turkey. Gastrointestinal involvement is between 1.4 and 3 in Turkey and up to 58% in Japan and 15% in Korea. [11] [12] [13] [14] It is of particular importance especially in Japan and Korea because it is still associated with significant morbidity and mortality in this region.
The skin pathergy test (SPT) positivity varies between geographic areas, and it is considered highly sensitive and specific for BD in patients from Turkey, some Mediterranean, the Middle Eastern countries and Japan. Interestingly, a number of studies from Japan and Turkey have reported a decline in the positive rate of SPT. Sakane et al. 6 reported positivity rate of 75% in 1972. The same rate was found to be at approximately 50% in the studies of Nishiyama et al. 15 in 2003 and Ideguchi et al. 13 in 2011. Similar trend have also been recognized in studies performed in Turkey. In the earlier studies, SPT positivity has been reported as 74% by Yazici et al. 16 and 67% by Dils ßen et al. 17 In our multicenter study, 11 we found this rate to be 37.8%. Recent surveys in Iran also revealed a remarkable decrease in the positivity of SPT. 18 Differences in the methodology used to perform SPT and racial differences may be the main reasons in the low prevalence of positive SPT. The more important reason seems to be the widespread use of disposable needles instead of blunt, reusable, sterilized needles. Recently Togashi et al. 19 have proposed a new diagnostic pathergy test to overcome this problem. They performed a skin prick test with neat and filter-sterilized saliva on the forearm skin. Ninety percent of BD patients showed an indurative erythema at the skin site pricked with self-saliva, whereas 60% of recurrent aphthous stomatitis (RAS) patients demonstrated a relatively weak reaction. Pricking with filter-sterilized saliva failed to produce any of the positive skin reactions. They suggested that skin prick test using self-saliva can be a simple and valuable in vivo diagnostic approach for differentiating BD and RAS from other mimicking mucocutaneous diseases. The positive skin prick may be triggered by resident intraoral microflora, particularly streptococci, and may in part address the underlying immunopathology in BD.
ETIOLOGY
Although several immunological abnormalities have been demonstrated, the exact mechanism of the inflammatory changes occurring remains to be elucidated. The most probable hypothesis is that of an inflammatory reaction set off by infectious agents such as herpes simplex virus (HSV)-1 or Streptococcus species such as Streptococcus sanguinis or by an autoantigen such as heat shock proteins (HSP) in genetically predisposed individuals. 20 Infectious agents have been suspected to play a role in the pathogenesis. Professor Hulusi Behc ßet was one of the first physicians asserting the role of an infectious agent, HSV-1, in the development of BD. 1 In particular, a possible association between HSV-1 with BD has been the subject of several investigations. Hybridization between HSV-1 DNA and complementary RNA in mononuclear cells was found to be higher in BD patients than the control patients. Results indicated the presence of at least a part of the HSV-1 genome in mononuclear cells of patients with BD. 21 In recent years, several streptococcal strains has gained increasing importance in infectious etiology. In this regard, the emergence of some clinical manifestations of the disease following hypersensitivity tests applied with streptococcal antigens in patients with BD was an important evidence. In addition, antibodies directed against Streptococcus pyogenes and S. sanguinis are obtained significantly more often in sera of BD patients than the control group. 22 Streptococcal 65-kDa HSP from an uncommon serotype (KTH-1, strain BD113-20) of oral S. sanguinis have been noted to be important extrinsic factors in the pathogenesis of BD. 4 Oral microbial flora have long been implicated in the pathogenesis, as BD starts mostly from the oral mucosal surfaces. 23 Dental interventions or tonsillitis have been indicated to result in disease attacks such as OU as well as activation of other manifestations. 24, 25 Antimicrobial agents including antibiotics and antiseptic agents have been used to control disease activation. 26 Previous and our studies demonstrated that oral health was impaired in patients with BD as compared with healthy controls. 20, 23, 27 Additionally, Mumcu et al. 23 observed elevated plaque index score to be a significant risk factor for increased severity score in patients with BD. Our study showed that periodontal scores were higher in BD patients compared with healthy controls and RAS. Moreover, increased periodontal scores were correlated with the severity of the disease.
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C ß elenligil-Nazlıel et al. 27 demonstrated that poor oral hygiene leads to rapid bacterial plaque accumulation. They suggested that the bacterial plaque ecology and/or immune responses to these microorganisms may be affected in BD which could lead to changes in the expression of periodontal disease. Improvement of the oral health of BD patients may affect their disease course, leading to a better prognosis. Karac ßaylı et al. 28 showed that, in BD patients, dental and periodontal therapies could be associated with a flare-up of OU in the short term, but may decrease their number in longer follow up. They also lead to a better oral health. Interestingly, several atypical streptococcal species were significantly high in the oral flora of patients with BD and a particular strain, S. sanguinis, has been shown to enable the KTH-1 cells to secrete the pro-inflammatory mediators of interleukin (IL)-6, IL-8 and tumor necrosis factor (TNF)-a in these patients. Therefore, it is entirely possible that in genetically predisposed individuals an inflammatory reaction set off by infectious agents, such as streptococcus species, could lead to development of BD. 29, 30 Genetic factors that predispose individuals to BD are considered to play important roles in the development of the disease. Familial aggregation studies in patients with BD indicate a strong genetic background and a complex inheritance model. 31 The association of BD and HLA-B5(51) was first defined by Ohno et al. in 1973. 32 Several studies in different ethnic groups confirmed the HLA-B51 association with BD. Still, association with HLA-B51 is known as the strongest genetic susceptibility factor for BD, and it is thought to play a role in neutrophil activation. In this regard, a recent meta-analysis showed that subjects carrying HLA-B51/B5 have an increased risk of developing BD with an odds ratio of 5.78 compared with non-carriers of this antigen. 33 However, the presence of HLA-B51 alone is not sufficient to explain all of the symptoms observed in BD and, in agreement with this, recent studies suggest the involvement of other genes. In a recent multicenter study, including our department, Hughes et al. 34 tried to localize the genetic association between HLA-B*51 and BD and explored additional susceptibility loci in the HLA region. In the extended HLA locus, 8572 variants were genotyped, and imputation and meta-analysis of 24 834 variants were carried out in two independent BD cohorts. The most significant association was with rs116799036. To determine whether the genetic effect of this single nucleotide polymorphisms (SNP) can be explained by the repeatedly reported genetic association between BD and HLA-B51, we performed pairwise conditional analysis to control for HLA-B-5101. The genetic association at rs116799036 remained significant, independent of HLA-B-5101, in Turkish and Italian cohorts. Notably, the genetic association with HLA-B51 completely disappeared when controlling for the genetic association with this SNP. Our data strongly suggest that the association between HLA-B51 and BD can be explained by this SNP, which is located in the promoter region of HLA-B, between the HLA-B and MICA genes. Therefore, we speculated that the risk previously ascribed to HLA-B51 is likely not causal with respect to BD. However, further functional studies are required to confirm the consequences of our findings.
Besides our study, a recent six genome-wide association studies, [35] [36] [37] [38] [39] [40] with the exception of the study by Fei et al., 35 have confirmed the association of BD with HLA-B51, and reported new susceptibility genes in the remaining part of the HLA class I region and several non-HLA genes for the disease. Two of them, conducted in Turkey 36 and Japan, 37 reported association between SNP of IL-10 and IL-23R/IL-12RB2 genes and BD. The disease-associated variants were located in the IL-23R side of the hot spot, suggesting that the association with BD is more likely to be with IL-23R rather than IL-12RB2. IL-23 which shares the p40 subunit with IL-12, acts to induce T-cell activation to produce IL-17 and therefore is one of the main T-helper (Th)17 pathway activators. Overexpression of pro-inflammatory cytokines, mainly Th1 and Th17 from various cellular sources, appears to be responsible for the enhanced inflammatory reaction in BD and may be associated with genetic susceptibility. Affected organs show significant neutrophil and lymphocyte infiltration. It is believed that the stimulated lymphocytes contribute to neutrophil and endothelial cell activation in these patients. 41 HSP have been speculated to trigger both innate and adaptive immunological reactions in patients with BD. Streptococcal 65-kDa HSP of oral S. sanguinis have been claimed to play important roles as an environmental factor in the pathogenesis. BD patients are thought to acquire the hypersensitivity against oral S. sanguinis through the innate immune system. Microbial load and associated stress proteins found in OU and periodontal tissues of patients with BD may cause a cross-reactivity with host tissues and stimulate the expression of autoreactive T-cell clones. HSP are considered to transfer antigenic peptides to antigen-presenting cells and they can be recognized by pattern recognition receptors (Toll-like receptors) to be an endogenous "danger" signal leading to activation of innate and adaptive immune responses. They may also, directly or indirectly, increase the expression of vascular endothelial growth factor by T cells, causing endothelial cell damage and vasculitis. 29 Current data suggest that Th17 cells and IL-17 may have a part in the development and/or activity of the disease. Hamzaoui et al. 42 reported increased serum levels of IL-17. Chi et al. 43 have
shown elevated production of IL-17, IL-23 and interferon (IFN)-c by peripheral blood mononuclear cells besides increased frequencies of IL-17-and IFN-c-producing T cells in BD patients with active uveitis. We investigated the role of IL-17 in the activity and different organ involvements of BD in 45 patients and 33 age-and sex-matched healthy controls. Serum IL-17 levels of BD patients were significantly higher than healthy controls. This difference is more pronounced in active BD patients compared with inactive BD patients and healthy controls. IL-17 levels of BD patients with active stages of uveitis, OU, GU and articular symptoms were significantly higher than patients with inactive stages of these symptoms. Compared with healthy controls, a significant increase was observed in the number of IL-17-producing cells obtained from BD patients after stimulation with S. sanguinis, Escherichia coli and phytohemagglutinin (PHA) in enzyme-linked immunospot. When we evaluated the proportion of IL-17-secreting cells in patients with active organ involvement, a significant increase in the percentage of IL-17, CD4 + IL-17 + and
CD4
-IL-17 + T cells after E. coli and PHA stimulation was observed. Taken together, our results indicate that Th17 and IL-17 pathways are active in BD patients, and play an important role, particularly in acute attacks of the disease. Increased neutrophil activity and neutrophil infiltration in the affected organs may be caused by increased IL-17 response in patients with BD. 44 Possible regulation mechanisms based on basic experimental evidence in the etiology of BD are summarized in Figure. 1.
MUCOCUTANEOUS LESIONS
Mucocutaneous lesions constitute the hallmark of the disease. The high frequency of OU and GU and cutaneous lesions at any time in the course of the disease, or as onset signs, confirm the importance of these clinical features for diagnosis. OU (92-100%), GU (57-93%) and cutaneous lesions (38-99%) together with ocular (29-100%) and articular (16-84%) involvements, are the most frequent features of the disease in all countries. Erythema nodosum (EN)-like lesions (15-78%) and papulopustular lesions (PPL) (28-96%) are the most commonly observed cutaneous lesions. 3 
Oral ulcers
Oral ulcers are characterized by recurrent and painful ulcerations of the oral mucosa. The most common sites are the mucous membranes of the lips, buccal mucosa, tongue and soft palate. The lesions start as an erythematous, slightly raised area with vesiculopustular lesion evolving into an oval or round ulcer within 2-3 days with rolled borders and a grayish yellow necrotic base. An erythematous halo surrounds the ulcers (Fig. 2a) . They are identical to conventional aphthae or RAS in appearance. However, Main and Chamberlain 45 reported that increased number of ulcers, concurrent variation in size from herpetiform to major aphthous, diffuse erythematous surrounds and involvement of soft palate and oropharynx may be useful to differentiate OU of BD from the conventional RAS. OU often subside spontaneously within 1-4 weeks and recur at intervals from days to months. Local trauma can induce new mucosal lesions (mucosal pathergy equivalent). OU can cause considerable pain and may result in difficulty when eating, drinking, speaking, swallowing and performing routine oral hygiene. 3 
Genital ulcers
Genital ulcers are similar in appearance and course to OU, but may not recur as often. They are usually deeper than the OU Figure 1 . Possible regulation mechanisms based on basic experimental evidence in the etiology of Behc ßet's disease (BD). Genetic factors are considered to play important roles in the development of BD. Association with human leukocyte antigen (HLA)-B51 is known as the strongest genetic susceptibility factor. Recent genome-wide association studies have confirmed this association and reported new susceptibility genes on the remaining part of HLA class I region and several non-HLA genes for the disease. Streptococcal 65-kDa heat shock protein (HSP) of oral Streptococcus sanguinis has been noted to be an important extrinsic factor in the pathogenesis. Microbial load and associated stress proteins found in oral ulcers and periodontal tissues of patients with BD may cause a cross-reactivity with host tissues and stimulate the expression of autoreactive T-cell clones. HSP can be recognized by pattern recognition receptors to be an endogenous "danger" signal leading to activation of innate and adaptive immune responses. They also increase the expression of adhesion molecules on endothelial cells. Overexpression of pro-inflammatory cytokines, mainly T-helper (Th)1 and Th17 cells appear to be responsible for the enhanced inflammatory reaction. Increased neutrophil activity and neutrophil infiltration in the affected organs may be caused by increased interleukin (IL)-17 response. The immune system activated at the end of all these complex processes is thought to eventually induce tissue damage and vasculitis. IFN, interferon; TNF, tumor necrosis factor. and heal within 10-30 days with a tendency to scar. The labia major is the most frequently involved site in females but the labia minor, vaginal mucosa and rarely cervix can also be affected. The scrotum is the most commonly involved site in males (Fig. 2b) . Ulcers can also be observed on the shaft and glans penis. Ulcers in the urethral orifice have also been reported. GU may occur in both sexes in the groin, perineal and perianal area. 3 GU may cause severe pain, difficulty with micturition, dyspareunia and marked difficulty in physical activity. Deep ulcers may scar and those in the vagina may be complicated by bladder or urethral fistulae.
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Cutaneous lesions 
Erythema nodosum-like lesions
Erythema nodosum-like lesions is mostly seen in females and occur in approximately one-third of all patients. They have a typical clinical presentation with bilateral, pretibial, painful and hot, erythematous nodules (Fig. 2c) . EN-like lesions can also be localized to the face, neck, forearms and buttocks. The lesions do not ulcerate and resolve spontaneously within 2-3 weeks in pigmented ethnic groups with residual pigmentation; however, recurrence is common. 41 Although they are clinically similar to those of classical EN secondary to other systemic causes, they differ from that condition with regard to their microscopic features. Vasculitis or vascular reactionunlike classical EN lesions -are the main features of these lesions, as they are in other cutaneous lesions of BD.
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Papulopustular lesions Papulopustular lesions are sterile, folliculitis-or acne-like lesions on an erythematous base which appear as a papule and in the course of a 24-48 h become a pustule. Trunk, buttocks (Fig. 2d ) and the lower limbs are the most common locations. 47 PPL were reported to be more frequent in patients with positive SPT 47 and arthritis. 48 
Superficial thrombophlebitis
Behc ßet's disease has been classified as variable vessel vasculitis which means the disease can affect vessels of any size and type. 49 The venous system is the major affected site, and superficial TFB is, indeed, the most frequent type of venous involvement. It is more common in males and frequently confused with EN-like lesions. Patients usually present with erythematous, tender, subcutaneous nodules arranged in a linear fashion (Fig. 2e) . The vein can be palpated as a string-like hardening because of thrombosis leading to vessel sclerosis with reddening of the overlying skin. The location of nodules shows a tendency to change from day to day because multiple segments of the vein may be involved. Superficial TFB is clinically important because it could frequently be associated with other forms of vascular disease in BD. Sarica-Kucukoglu et al. 50 evaluated the prevalence and types of vascular involvement in BD. Among 2319 patients, prevalence of vascular involvement was 14.3%, and superficial TFB was the most common vascular symptom (53.3%).
Other cutaneous lesions
Extragenital ulcers resemble other aphthous lesions of the disease. They are recurrent and usually heal with scarring. Extragenital ulcers, although not frequently seen, are among the 
Skin pathergy test
The SPT is a non-specific skin hyperreactivity induced by needle prick. The test positivity is defined as the development of a papule or pustule at the needle-prick site after 24-48 h (Fig. 2f) . It is similar to the spontaneously occurring PPL of the disease, and more strongly positive among males. Bacterial cultures of the SPT are negative. 3 
CLINICAL COURSE
Mucocutaneous lesions figure prominently in the presentation and diagnosis, and may be considered the hallmarks of the disease. Therefore, their recognition may permit earlier diagnosis and treatment. BD runs a chronic course with unpredictable exacerbations and remissions. The natural course of the disease is not fully known. Our previous multicenter 11 and recent single center 52 studies showed that OU are the most common manifestation followed by GU, PPL, EN-like lesions and articular and ocular involvement. OU were also the most common onset manifestation which was followed by GU, EN-like lesions and ocular involvement. In approximately 15% of the patients, more than one symptom appeared at the same time as the onset manifestation. OU and GU were the most common combination among the simultaneous occurrence of symptoms. Each or any combination of mucocutaneous, articular and ocular symptoms of the disease may have significant pain or loss in function, or both. Besides considerable morbidity, the disease confers an increased mortality, mainly because of pulmonary as well as large vessel involvement, neurological involvement and bowel perforation. Mortality ratios as well as mucocutaneous and articular manifestations usually tend to decrease significantly with the passage of time. Kural-Seyahi et al. in a two-decade outcome survey of 387 patients with BD noted a significant decrease in the proportion of all mucocutaneous disease manifestations (OU, GU, EN-like lesions and PPL) and arthritis at the end of the study. 53 Both the onset and the greatest damage of ocular involvement are usually within the first few years of the disease onset. However, recent studies and our studies demonstrated that neurological, gastrointestinal and large vessel involvements are exceptions, and can have their onsets later (5-10 years) during the course of the disease. 11, 13, 52, 53 Higher frequency of serious manifestations, such as ocular, 11, 52, [54] [55] [56] [57] vascular 11, 52, 56, 57 and neurological involvement, 11, 56, 57 have been reported in male patients, as detected in our studies. Association of male sex with heart 56 and renal 58 involvement has also been reported. On the other hand, ENlike lesions and articular involvement are more common in female patients. 11, [55] [56] [57] Current published work and our experience indicate that BD usually starts with relatively milder manifestations, and severe involvements, in general, appear later. Mucocutaneous lesions, especially OU and/or GU usually precede possible serious involvements. Therefore, careful follow up is mandatory because the disease shows a continuous activity. Male sex, younger age of onset and increased number of organs involved at the diagnosis are associated with a more severe disease, and therefore, require more aggressive treatment.
DIAGNOSIS
Because of the lack of a universally recognized pathognomonic laboratory test, the diagnosis of BD is primarily based on clinical criteria following the exclusion of an alternative diagnosis. Various criteria have been used, and most of them rely heavily on mucocutaneous manifestations, particularly OU, GU, cutaneous vasculitic lesions and the SPT. International Study Group for Behc ßet's Disease criteria, 59 briefly "ISG" criteria, which depend on the presence of recurrent OU, plus any two of recurrent GU, typical ocular lesions, typical cutaneous lesions or a positive SPT, remain the most widely used and well-accepted criteria among experts. An international team developed new criteria under the name International Criteria for Behc ßet's Disease, briefly "ICBD" criteria, which were published in 2006. These new criteria were revised in 2013, becoming the 17th set of classification/diagnosis criteria for BD. In this criteria, OU, GU and ocular manifestations get each 2 points, and others (skin lesions, neurological manifestations, vascular manifestations and positive SPT) get 1 point. If a patient gets 4 points or more, the patient is diagnosed as having BD. 60 The performance of ISG criteria versus ICBD revised criteria were checked in different cohorts. These studies indicate that ICBD revised criteria are more sensitive, and therefore diagnosis may become easier using these criteria. However, they are less specific than the ISG criteria, which means that the new ICBD revised criteria may cause overdiagnosis, Therefore, they should be interpreted cautiously. 61 The Japanese Diagnostic Criteria, 62 one of the most sensitive and specific, and the most commonly used criteria especially in the Far East countries, include four major symptoms (OU, skin lesions, eye lesions and GU) besides the minor ones (arthritis, intestinal ulcers, vascular disease, neuropsychiatric disorders and epididymitis). Patients with four major symptoms during the clinical course are defined as having complete BD; and those patients with three major symptoms, with two major and two minor symptoms, with typical recurrent ocular inflammation and one or more major symptom, or with typical recurrent ocular inflammation and two minor symptoms, as having incomplete BD.
HISTOPATHOLOGY
The histopathological features of BD are characterized by mainly vasculitis and thrombosis. As a general rule, larger vessel involvement tends to be vasculitic with often thrombosis or aneurysm, and mucocutaneous lesions often have features of a leukocytoclastic vasculitis or a neutrophilic vascular reaction. Mucocutaneous lesions, for example, OU, GU, EN-like lesions, superficial TFB, PPL and SPT, do not regularly present as vasculitis. Histopathological assessment of early cutaneous lesions often have features of a leukocytoclastic vasculitis. On the other hand, histopathological assessment of late lesions describe primarily a lymphocytic perivasculitis. Neutrophil activity is increased in BD, and the affected organs show a significant neutrophil and lymphocyte infiltration. Therefore, vasculitis is not the case for all patients, and a neutrophilic vascular reaction without vasculitis can be seen in many cases.
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TREATMENT Treatment of BD depends on a number of factors such as involved organ/s and severity of this involvement/s, frequency of recurrences, disease duration, age at disease onset and sex. However, the main aim of the treatment should be the prevention of irreversible organ damage, especially during the early, active phase of the disease. Therefore, close monitoring, and early and appropriate treatment is mandatory to reduce morbidity and mortality. The treatment is mainly based on the suppression of inflammatory attacks of the disease using immunomodulatory and immunosuppressive agents. Based on the mainly controlled studies and personal experience in clinical practice and basic research in this field, a stepwise, Amlexanox versus placebo Decrease in the pain severity and healing duration [78] [79] [80] 5-aminosalicylic acid versus placebo Decreases the healing duration 81 Tetracycline versus placebo Reductions in ulcer duration, size and pain 72, 73 Triclosan versus placebo Reduces the number of aphthous ulcers 74 Camel thorn distillate versus placebo Reductions in ulcer size and the pain severity 
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Topical treatment
The number of controlled studies is still limited. The majority of experience in the treatment of OU in patients with BD comes from the studies performed in patients with RAS. OU of BD are identical to RAS in appearance. Therefore, therapeutic remedies related with RAS, to some extent, can be applied to OU of BD. 26 The main topical therapeutic agents used in the treatment of BD and RAS in randomized controlled studies are summarized in Table 1 89, 90 are other alternatives for topical treatment of OU. In addition to the above-mentioned treatment approaches to OU, patients should be advised to maintain good daily oral hygiene. These patients should avoid irritating agents such as acid, crusty, hard, spicy or salty nutrients and alcoholic beverages. EN-like lesions are treated topically like those of classic EN. Wet dressings such as aluminum acetate 3-5% (Burow's solution) can be applied in the early stage of these lesions. This approach is also helpful for the treatment of superficial TFB. All therapy should be combined with bedrest. 26, 66 However, it is very important for clinicians to be aware that topical treatment has a great possibility of having only local effects and should almost always be associated with systemic therapy.
Systemic treatment
Activity spectrum of systemic therapeutic agents on BD in randomized controlled studies is summarized in Table 2 . The treatment algorithm for mucocutaneous BD summarized below are mainly based on controlled studies. 66, 67 In Figure 3 , I have tried to recommend the most appropriate treatment we have already used in our clinical practice. In the treatment of OU, GU, EN-like lesions and PPL, colchicine should be the first choice. [91] [92] [93] If this is not effective, colchicine can be combined with benzathine penicillin. 94, 95 Shortterm corticosteroids in combination with other drugs such as colchicine can be used as an alternative in the treatment of acute attacks of OU, GU, EN-like lesions and superficial 100 and rebamipide 101 can be other choices, however, there is still a need for well-organized newer studies of these agents. Cyclosporin, 102, 103 apremilast, 104 IFN-a, 105 anti-TNF-agents 106 and isotretinoin 107 are other alternatives to control the disease in unresponsive cases.
New biological treatments
There is a general agreement that wider use of biologics such as anti-TNF-a agents, yielded clinically significant improvements in the majority of patients. Almost all trials with anti-TNF-a agents, infliximab, adalimumab and etanercept reported encouraging results for recalcitrant mucocutaneous lesions besides ocular and gastrointestinal symptoms, arthritis and cerebral vasculitis. 66, 115 Other biologics such as IL-1, -2, -6, -12, -17 and -23-blocking agents and monoclonal antibody against CD20 have been increasingly used in recent years in patients with BD refractory to other treatments. Most of the studies related to the respected biologics concentrated on the eye disease or other major organ involvements. Only a few of them evaluated the responses of individual mucocutaneous manifestations. Vitale et al. 116 used canakinumab, an IL-1b inhibitor, in three patients and reported prompt and sustained clinical efficacy in OU and GU besides ocular and gastrointestinal symptoms. Cantarini et al. 117 used anakinra, a recombinant human IL-1 receptor antagonist, in nine refractory BD patients. Eight of them showed a prompt improvement after starting anakinra, supporting the concept that IL-1 plays a pathological role in this disease. However, OU, GU and skin lesions were the most frequent manifestations refractory to anakinra, with a poor response in seven out of nine patients. On the other hand, tocilizumab, an IL-6 receptor antibody, seems to be ineffective in the treatment of mucocutaneous BD while it was reported to be effective on neurological involvement. 118 Ustekinumab, a human monoclonal antibody against the common p40 subunit of IL-12 and IL-23, was used in a patient with BD, psoriasis and hidradenitis suppurativa. Baerveldt et al.
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reported a complete response within 3 months without adjunctive immunosuppressive treatment in all three diseases. Zhao et al. 120 presented a challenging case of BD with OU, GU, ENlike lesions and arthritis. Rituximab treatment, a chimeric monoclonal antibody against CD20, resulted in marked clinical improvement by allowing for reduction in steroid requirements.
In conclusion, as a high incidence of vital organ involvement, as well as the increased mortality has been recorded in patients with BD, continuous surveillance and good management of the disease is warranted. Working in collaboration with other specialties to improve patient outcomes in the management of BD is mandatory. In this respect, patient-based organizations that now are allied with cognizant physicians should be encouraged. Treatment has become much more effective in recent years because of advances in understanding the pathogenesis of the disease, and introduction of more effective and specific newer drugs. New treatments may help improve BD patients' outcomes. Alleviation of most symptoms, control of the disease or even modification of the course of the disease are now possible.
